Lexicon Pharmaceuticals, Inc. (LXRX)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
Currency in USD
Valuation measures4
| Market cap (intra-day) | 464.16M |
| Enterprise value | 214.83M |
| Trailing P/E | 3.74 |
| Forward P/E | N/A |
| PEG ratio (5-yr expected) | N/A |
| Price/sales (ttm) | 191.95 |
| Price/book (mrq) | 1.61 |
| Enterprise value/revenue | 93.00 |
| Enterprise value/EBITDA | N/A |
Trading information
Stock price history
| Beta (5Y monthly) | 1.38 |
| 52-week change 3 | -34.15% |
| S&P500 52-week change 3 | 26.43% |
| 52-week high 3 | 3.7300 |
| 52-week low 3 | 0.9200 |
| 50-day moving average 3 | 2.0476 |
| 200-day moving average 3 | 1.6699 |
Share statistics
| Avg vol (3-month) 3 | 4.5M |
| Avg vol (10-day) 3 | 3.2M |
| Shares outstanding 5 | 246.24M |
| Implied shares outstanding 6 | 246.24M |
| Float 8 | 99.98M |
| % held by insiders 1 | 1.69% |
| % held by institutions 1 | 81.67% |
| Shares short (15 Apr 2024) 4 | 20.12M |
| Short ratio (15 Apr 2024) 4 | 6.39 |
| Short % of float (15 Apr 2024) 4 | 42.17% |
| Short % of shares outstanding (15 Apr 2024) 4 | 8.17% |
| Shares short (prior month 15 Mar 2024) 4 | 21.35M |
Dividends & splits
| Forward annual dividend rate 4 | N/A |
| Forward annual dividend yield 4 | N/A |
| Trailing annual dividend rate 3 | 0.00 |
| Trailing annual dividend yield 3 | 0.00% |
| 5-year average dividend yield 4 | N/A |
| Payout ratio 4 | 0.00% |
| Dividend date 3 | N/A |
| Ex-dividend date 4 | N/A |
| Last split factor 2 | 1:7 |
| Last split date 3 | 21 May 2015 |
Financial highlights
Fiscal year
| Fiscal year ends | 31 Dec 2023 |
| Most-recent quarter (mrq) | 31 Mar 2024 |
Profitability
| Profit margin | 0.00% |
| Operating margin (ttm) | -4,011.77% |
Management effectiveness
| Return on assets (ttm) | -40.08% |
| Return on equity (ttm) | -102.72% |
Income statement
| Revenue (ttm) | 2.31M |
| Revenue per share (ttm) | 0.01 |
| Quarterly revenue growth (yoy) | 4,608.30% |
| Gross profit (ttm) | N/A |
| EBITDA | -185.36M |
| Net income avi to common (ttm) | -193.58M |
| Diluted EPS (ttm) | -0.8300 |
| Quarterly earnings growth (yoy) | N/A |
Balance sheet
| Total cash (mrq) | 355.6M |
| Total cash per share (mrq) | 1.44 |
| Total debt (mrq) | 106.24M |
| Total debt/equity (mrq) | 36.78% |
| Current ratio (mrq) | 15.58 |
| Book value per share (mrq) | 1.17 |
Cash flow statement
| Operating cash flow (ttm) | -185.41M |
| Levered free cash flow (ttm) | -111.15M |
© 2024 Yahoo. All rights reserved.